|Grant Number:||5R21CA164121-02 Interpret this number|
|Primary Investigator:||Bradbury, Angela|
|Organization:||University Of Pennsylvania|
|Project Title:||Virtual Cancer Genetic Services: Telemedicine Delivery in Community Clinics|
DESCRIPTION (provided by applicant): Basic science advances in genomics have provided great promise for improving human health and reducing the burden of cancer in the United States, fueling the rapidly growing field of personalized medicine. Yet, translating gene discoveries into responsible and effective applications that benefit the health of individuals and populations presents many challenges. Genetic screening for cancer susceptibility is one application of "personalized medicine", which has become standard of care in clinical medicine. Given the increasing demand for genetic testing and the desire to disseminate services broadly to optimize population health benefits, the current delivery model for genetic testing in oncology presents barriers to widespread dissemination of genetic testing. Telemedicine (e.g. videoconferencing) has been successfully used to expand a variety of specialized medical services to low access populations. Yet, there are significant gaps in our understanding of the impact of telemedicine at both individual and population levels. Further research is needed to develop and evaluate telemedicine communication, delivery, and dissemination strategies to optimize outcomes of telemedicine genetic services, in and beyond cancer genetics. The diffusion of cancer genetic services provides an ideal context to evaluate the dissemination of telemedicine delivery of cancer genetic services, and to assess and understand the real world outcomes of personalized medicine in diverse populations. We propose to develop a protocol for telemedicine (i.e. videoconferencing) delivery of cancer genetic services, and evaluate the feasibility of implementing it in community clinical practices with limited or no access to on-site genetic services, expanding the availability of personalized cancer risk assessment to populations where access to services has been limited or is associated with significant barriers to utilization. In Aim 1, we will collaborate with community practices to develop and pilot a protocol for telemedicine cancer genetic services for community practices with limited or no access to genetic services. In the pilot, we will use providers (genetic providers & community site staff) and patient surveys to refine the telemedicine protocol and procedures. In Aim 2, we will conduct semi-structured interviews with key practice stakeholders from 10-12 additional community practices to identify variables critical to the sustainable adoption and implementation of our telemedicine protocol in diverse clinical community practices with limited or no access to genetic services. We expect this research to inform future efficacy and effectiveness research focused on broader implementation of, and sustainability telemedicine cancer genetic services in community practices. Additionally, we expect this research to inform the dissemination of other emerging and new applications of personalized medicine, fostering the translation of research to clinical practice, and promoting the health of individuals, families and populations.
Uptake And Timing Of Bilateral Prophylactic Salpingo-oophorectomy Among Brca1 And Brca2 Mutation Carriers
Authors: Bradbury A.R. , Ibe C.N. , Dignam J.J. , Cummings S.A. , Verp M. , White M.A. , Artioli G. , Dudlicek L. , Olopade O.I. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2008 Mar; 10(3), p. 161-6.
Controversies In Communication Of Genetic Screening Results For Cancer: A Report From The American Society Of Preventive Oncology's Screening Special Interest Group (aspo's 33rd Annual Meeting, March 8 To 10, 2009, Tampa, Florida)
Authors: Patrick-Miller L. , Bradbury A.R. , Terry M.B. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2010 Feb; 19(2), p. 624-7.